Skip to content

FRA:ANU1

Featured image XORTX - Dr. Allen Davidoff, President and CEO

XORTX Therapeutics (FRA:ANU1 | CSE:XRX | OTCQB:XRTXF): Redefining kidney disease treatment

A publicly-listed biopharmaceutical company with three clinically advanced products in development, XORTX Therapeutics’ focus is on developing drugs for kidney disease treatment, an area where there is a large unmet
Read More